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Cervical cancer is the primary lethal malignancy for women worldwide, but because it develops over time, it would be one of 
the most preventable types of cancer.  Dysregulation of apoptosis in cells plays a critical role in the malignancy development. 
Survivin is the smallest inhibitor apoptotic protein (IAP) which has an important part in regulating cell division and inhibitor 
of apoptosis. This review focused on survivin features in cervical cancer from mechanisms of malignancy relationship to 
human papillomavirus (HPV) infection through E6 oncogenic protein, role as a biomarker in diagnosis, prognosis, staging 
and prediction of metastasis, and also as a target for therapy. Regulation of survivin divided into two main groups; cell 
cycle dependent and cell cycle independent pathway to maintain life and death balance. Survivin expression is upregulated 
by E6 protein simultaneously repressing p53. Thus cancerous cervical tissue developed. Survivin is also upregulated in 
hypoxia, a common condition in many tumors and increased angiogenesis. Survivin plays a significant role in chemotherapy 
and radiation resistance in many cases of cervical cancer. As a target of therapy, survivin has a promising performance, 
suggested very specific, no issue of resistance and also enhance the effectiveness of chemo and radiation therapy. The 
goal of treatment is to lower survivin expression through transcription inhibition, immunotherapy based on cytotoxic T 
lymphocytes (CTL) activity and gene therapy.  
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Introduction
Cervical cancer
Cervical cancer is the primary lethal malignancy for women 
worldwide, but because it develops over time, it would be 
one of the most preventable types of cancer.1,2 Cervical 
cancer is the most easily cured cancer if detected as soon 
as possible. Cervical cancer started from the lower part of 
the uterine and happened when the cells proliferate out of 
control. The primary cause of cervical cancer is high-risk 
type human papilloma virus (HPV).2
 HPV infection and transmission in human passed 
through genital contacts.2,3 If the HPV infection became 
persistent, it will develop cancer over time.2 Several types of 
HPV have identified in aggressive cervical cancer, whereas 
others are associated with dysplasia or carcinoma in situ. 
The known 13 types of high-risk HPV (HR-HPV) are 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.2,3 Until 
now, the assessment of prognosis cervical cancer seen from 
a tumor marker. Clinico-histopathological tumor developed 
to determine prognostic factors for cervical cancer as viewed 
antigen serum, angiogenesis factors and apoptosis factor.4 
C e l l  a n d 
B i o p h a r m a c e u t i c a l 
I n s t i t u t e
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Dysregulation of apoptosis in cells plays a significant role 
in the development of cancer malignancy.5
Pathophysiology of cervical cancer
The development of oncogenic HPV infection into cervical 
cancer occurs if the infection settled. The development 
of abnormal cells in cervical epithelium can develop into 
precancerous also called cervical intraepithelial neoplasia 
(CIN).1 Developmentally abnormal cells become cancerous 
is following:
1. CIN I/low-grade squamous intraepithelial lesions 
(LSILs): in this stage, there is a change that cells 
infected with oncogenic HPV will make new virus 
particles.
2. CIN II/high-grade squamous intraepithelial lesions 
(HSILs): the cells continued to show symptoms of 
abnormal precancerous. 
3. CIN III: surface layer of the cervix filled with the 
abnormal cells and may involve the full thickness. 
CIN III is usually caused by certain types of HPV. If 
not treated, these abnormal cells become cancer and 
infected normal tissues. 
4. Invasive cervical cancer.
Types of cervical cancer 
Classification of cervical cancer and pre-cancer determined 
by how they appearance on the microscope. The major 
types of cervical cancer are squamous cell carcinoma (SCC) 
and adenocarcinoma. SCC developed from exocervix cells 
and began the abnormal transformation within the joints 
of endocervix and exocervix area. On the other hand, 
adenocarcinoma developed from gland cells which produce 
mucus in the endocervical area. SCC considered as the 
most commonly cervical cancer, but in the past 30 years, 
adenocarcinomas become more frequent. Another type 
but less common, mixed of squamous cell carcinoma and 
adenocarcinoma, termed as adenosquamous carcinoma.1
Survivin
To inhibit the growth of cancer cells from invading normal 
cells should be quick and appropriate. The standard 
treatments such as surgery, chemotherapy and radiotherapy 
have yielded significant results in inhibiting the growth of 
cancer cells. But the development of drug resistance and the 
occurrence of cancer metastasis remains a challenge that 
is difficult to control.6 Immunotherapy is one of the type 
cancer therapy designed to trigger adaptive immune system 
to fight cancer and prevent metastasis. Normal cells will die 
by itself if it suffered damage to its deoxyribonucleic acid 
(DNA), but not so in cancer cells; they do not have the ability 
to detect defects and resistance to apoptosis. The ability of 
cancer to escape from the immune system is the one of 
primary evasion mechanism, and at the same time, they can 
promote their proliferation.6 Survivin found overexpressed 
in cancer cells which suggested to have a significant role in 
the regulation of T-cell responses and becomes a potential 
for targeted cancer therapy.7 On the other hand, survivin 
has a role in angiogenesis. Thus, survivin promotes cell 
proliferation and migration in the survival of cancer from 
apoptosis.8 
 Survivin also called baculoviral inhibitor of apoptosis 
repeat-containing 5 (BIRC5), which is the smallest inhibitor 
of apoptosis protein (IAP) N-terminus with a single 
baculovirus IAP repeat (BIR) domain and the C-terminus 
coiled coil (CC) domain.7 Survivin has 142 amino acids and 
molecular weight of 16.5 kDa. Compared with other IAPs, 
Survivin has an important role in regulating cell division and 
inhibitor of apoptosis. In the cell cycle, survivin expressed 
at the Gap 2/mitosis (G2/M) phases.5 This condition makes 
survivin is potential because it can be a promising therapy 
for cancer. The expression of survivin in CIN I, CIN II 
and CIN III had increased significantly, suggested that 
survivin could be a useful marker for the diagnosis and 
differentiate the value of CIN patients.9 Survivin expression 
also correlated with the patient's clinical stage.6,9 Survivin 
expression in tumors is also associated with a high rate of 
disease recurrence and resistance to therapy, and it confers a 
significant survival advantage to tumor cells.10
Expression regulation of survivin
Dysregulation of survivin is a key of many types of cancer. 
Survivin expression associated with an unusual activation 
of some receptor tyrosine kinases (RTKs), for example, 
epidermal growth factor receptor (EGFR), erythroblastosis 
oncogene B (ErbB-2)/human epidermal growth factor 
receptor 2 (HER2), insulin-like growth factor-1 (IGF-1) 
and IGF-1 receptor (IGF-1R). Other receptors including 
viability signal cascades of cells  (phosphatidylinositol-3-
kinase and protein kinase B or PI3K/Akt), mammalian target 
of rapamycin (mTOR), signal transducer and activator of 
transcription (STAT), hypoxia-inducible factor-1  (HIF-1), 
etc.11 Different regulation of survivin expression occurs 
in cycle-dependent pathways; there are transcriptional 
level and post-translational regulations and cell cycle-
independent pathway.
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Cycle-dependent pathway
a. Transcriptional level regulation
Survivin genome sequences contain a cell cycle-dependent 
element (CDE)/cell cycle genes (CHR) in the promoter 
region, showing that survivin can be cell cycle-regulated 
gene. Many kinds of micro-ribonucleic acid (miRNA) are 
identified to regulate survivin’s expression via binding to 
3’-untranslated (UTR) region of survivin’s messenger RNA 
(mRNA), so that produce protein translational changes 
leading to the mRNA degradation. 
 miRNA is non-encoding small RNA expressing 
various post-transcriptional target genes. Downregulation 
of miRNA-218 (miR-218) has reported in some dangerous 
human cells including cervical cancer, lower miRNA-218 
serum level that has been described due to tumor invasion.12
b. Post-translational level regulation
Survivin level influenced by protein modifications 
like phosphorylation and polyubiquitination. Survivin 
phosphorylation at threonine 34 (Thr34) by cell division 
cycle protein 2 (CDC2), which also called cyclin-dependent 
kinase 1 (CDK1) has an effect of stabilizing surviving during 
prometaphase and metaphase of proteasomal degradation 
and prolong anti-apoptotic threshold in the cells which 
undergo mitosis. Survivin's phosphorylation at Thr48 has 
an effect to change the binding with borealin and thereby 
affects its ability to enhance cell proliferation and inhibits 
cell death.13
 The ubiquitin-proteasomal pathway is also identified 
to regulate survivin’s degradation in a cell cycle-dependent 
manner and BIR domain of surviving essential to keep its 
stabilization at G2/M phase on post-translation.
Cycle-independent pathway
Cycle-independent mechanism affecting survivin’s 
expression level involves hematopoietic response and 
cytokine vascular remodeling, STAT3-dependent signal 
transduction and PI3K activity, angiopoietin-1 (ANG1), 
interleukin 11 (IL-11), STAT3 signal transducer and 
transcription activator.11
 Survivin expression associated with the unusual activity 
of several RTKs, such as EGFR, HER2, HER3 and IGF-1. 
These kinases can trigger various viability signal cascades 
like P13K/Akt-mTOR organizing survivin’s expression. 
Phosphorylated serine 81 (Ser81) survivin induce activity 
of protein kinase A (PKA) in the cryoprotection mechanism 
via P13K.14
Molecular mechanism of survivin in 
tumorigenesis
Survivin involved in tumorigenesis through some different 
mechanisms including apoptotic inhibition, cytokinesis 
regulation, cell cycle progression and the participation in 
many kinds of pathway like p53 signaling, wingless-related 
integration site (Wnt), transforming growth factor (TGF) 
and Notch pathways.7
Survivin’s mechanism in apoptotic pathway
As an IAP, survivin protects cells against apoptosis by 
inhibits caspase. However, survivin isn't able to bind and 
directly inhibits caspase rather interacts with pro- and anti-
apoptotic proteins. Thereby survivin should form a complex 
with X-linked IAP (XIAP), an IAP directly binding caspase, 
resulting in increased XIAP stability and to proteasomal 
degradation.
 There are two apoptotic mechanisms known in 
mammals: intrinsic and extrinsic apoptotic. These both 
pathways are executed by some caspase proteins, such as 
initiator caspase (caspace-8 and -9) and executioner caspase 
(caspase-3, -6 and -7). Apoptosis initiated by cytochrome 
c binding cardiolipin within the inner mitochondrial 
membrane and activating caspase-9. Caspase-9 further 
activates caspase-3 and -7 which are responsible for 
cells damage. Survivin overexpression associated with 
apoptotic inhibition initiated by extrinsic and intrinsic 
apoptotic pathways. An in vitro study indicates that 
survivin phosphorylation at Thr34 and CDC2 is necessary 
for survivin interaction with caspase-3, -7 and -9. Several 
further studies found that a survivin mutation at Thr34 can 
induce cytochrome c release from mitochondria leading 
to apoptosis. Phosphorylated survivin at Thr34 by CDK1 
can protect cells against cell death by inhibiting caspase-9 
during mitosis.15 Beside Thr34, Ser81 is also reported to 
enhance cell protection, although treated by tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand (TRAIL).16
 The gene that encodes a protein survivin is BIRC5 
have the 17q25 locus will affect apoptotic pathways by 
action on the caspases and increase cell division. Survivin in 
cervical cancer can inhibit apoptosis through two pathways. 
The first path is to upgrade with CDK4 as well as the release 
of p21. The second pathway is by inhibiting the activity of 
caspase-7 and caspase-3.13,17
 Functional study on cervical cancer showed that by 
suppressing survivin expression in HeLa cells causing 
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spindle impairment and promoting apoptosis.8 Disruption of 
the expression and function of apoptotic inhibitor survivin 
cause caspase-dependent cell death during the G2/M 
phase of cell cycle and cell division impairment indicated 
by centrosome dysregulation, multipolar and nuclear 
mitotic spindle, polyploidy cells.19 Anti-apoptotic function 
conducted by cytoplasm survivin, whereas nuclear survivin 
is involved in cell division setting.20
Survivin’s mechanism in cell cycle
In several studies noted that survivin expression regulated 
by cell cycle and loops during the G2/M phase, and down 
fast during the G1 phase. Survivin is dynamically located in 
the different region of the chromosome during the cell cycle. 
As long as mitosis, survivin serves as a part of chromosomal 
passenger complex (CPC).21
 CPC is consists of a localization module and a kinase 
module, which connected by inner centromere protein 
(INCENP) center. Localization module composes INCENP 
N-terminal and borealin as well as surviving C-terminal, 
leads first CPC into centromere, then mitotic spindle and 
ultimately into midbody. Survivin is responsible for leading 
CPC into centromere at early prophase. The BIR domain 
binds the N-terminal of phosphorylated histone H3 at Thr3; 
a mitotic-specific phosphorylation clearly marks the inner 
centromere.22
 Survivin accumulates in the centromere during the 
G2 phase and then begins to diffuse with the chromosome 
arms and abundant in the middle of centromere during 
prophase and metaphase in mitosis. In anaphase, survivin is 
localized at mid/center of spindle because it failed to bind 
the centromeres. During cytokinesis, survivin concentrated 
in the middle. Cell cycle-specific regulation of surviving 
noted that survivin plays a significant role in cancer cell 
proliferation. Also, survivin could be phosphorylated by 
CDK1 which is a critical kinase for cell cycle regulation.23
Survivin mechanism in cancer
Survivin overexpression in cancer is related to mutation 
inside the promoter, gene duplication or dysregulation 
of related transcriptional factors. P532, for example, 
functionally inactivated by mutations in several types of 
cancer, seems to suppress survivin’s mRNA transcription. 
Nuclear factor-kappa B (NF-kB) induction and avian 
myelocytomatosis virus oncogene cellular homolog 
(c-Myc) expression via P13K/Akt pathway are also leading 
to survivin overexpression in a cell cycle-independent 
manner in tumor cells.24
 Survivin aberrant expression and p53 wildtype 
disruption associated with tumorigenesis. There is a 
significant possibility that survivin functionally binds 
p53. Many studies indicated that p53 wildtype could also 
suppress survivin expression in transcriptional level and the 
loss of survivin function partially mediates p53-dependent 
apoptotic pathway. Further analysis via chromatin 
deacetylation of survivin promoter shows that chromatin 
modification can contribute in surviving expression 
silencing by p53.8
 Survivin facilitates cancer cells defense and 
proliferation, thus increase angiogenesis, a process providing 
oxygen as well as a nutrient for emerging unavoidable 
tumor which allows the tumor growth beyond the certain 
size. Survivin enhances angiogenesis by stimulating tumor 
cells to express and secrete increased number of vascular 
endothelial growth factor (VEGF) which is an essential 
signaling molecule in all angiogenesis step. P13K/Akt 
signaling and β-catenin-T-cell factor/lymphoid enhancer 
factor (TCF/LEF)-dependent transcriptions were involved 
in many related cancer genes expression, including survivin 
and VEGF.25
 Survivin expression is not only upregulated in cancer 
cells but also in tumor vascular endothelial cells. In the 
tumor, IAP survivin had pleiotropic function and associated 
with tumor progression, metastasis and angiogenesis. The 
mechanism includes interaction and stabilization of complex 
anti-apoptotic protein XIAP and pro-apoptotic protein 
inhibition such as second mitochondria-derived activator 
caspases (SMAC)/direct inhibitor of apoptosis-binding 
protein with low pI (DIABLO) or apoptotic inducing 
factor (AIF). Recently, this survivin promotes invasion 
and metastasis by increasing NF-kB cells activated by NF-
kB-dependent transcription of fibronectin. Intramolecular 
between XIAP and survivin triggers tumor cell invasion 
and increases metastasis. This pathway is independent of 
IAP inhibition of cell death. On the contrary, a complex 
survivin-XIAP activates NF-kB, which in turn causes 
increased fibronectin gene expression, signaling by integrin 
beta-1 and motility cell activation by focal adhesion kinase 
(FAK) and sarcoma (Src) kinase.25
Survivin mechanism in Wnt/β-catenin
During tumorigenesis, β-catenin accumulation in the 
cytoplasm known as Wnt signaling pathway hallmark. 
Then Wnt signaling induces β-catenin translocation into 
the nucleus to form β-catenin factor/TCF transcription 
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activator conducts upregulation of target genes such as 
survivin, c-Myc and VEGF. Increased survivin expression 
then protects the cells from apoptosis and increase cancer 
cell proliferation.26
 Survivin expression associated with increased 
β-catenin/TCF-LEF reporter activity via P13K/Akt-
dependent mechanism. Thereby, increased expression and 
many target genes including VEGF accumulation occurs, 
which will promote angiogenesis. The connection between 
those markers involved in angiogenesis illustrated in Figure 
1. Casein kinase 2 (CK2) also promotes tumor cell’s viability 
and inhibits apoptosis by involving increased β-catenin/
TCF-LEF transcriptional genes.27  
Survivin mechanism in hypoxia signaling
Hypoxia contributes to various biological processes such as 
angiogenesis, malignancy, metastasis and therapy resistance. 
While in response to hypoxia, the cells undergo gene 
expression change initiated by the HIF-1 transcriptional 
factor, which is heterodimeric protein complex consists of 
HIF-1α and HIF-1β responsible of metabolic adaptation, pH 
controlling and neovascularization process.28 
 HIF-1α protein expression is negatively regulated 
in cells nonhypoxic by ubiquitination and proteasomal 
degradation. In hypoxic conditions, the levels of HIF-1α 
protein will increase dramatically. Overexpression of HIF-
1α may occur in conditions of intratumoral hypoxia and 
genetic changes that activate the transcription of genes 
involved in cancer biology, glucose metabolism, cell 
proliferation, apoptosis, invasion and prognosis of cancer.
 Hypoxic conditions lead to increased activation of 
survivin promoter, wherein the first 158bp of survivin gene 
promoter sequence into port responsive to hypoxia. Several 
mechanisms between HIF-1 and survivin in hypoxia, among 
others:
1. HIF-1 can bind to other DNA sequences directly in the 
promoter region of survivin,
2. HIF-1 binding indirectly through interactions with 
transcription factor protein proteinuria as activator 
protein 1 (AP-1), specificity protein 1 (Sp1) and the 
effects of c-Myc indirectly affect the expression of the 
target gene HIF-1,
3. HIF-1 induces the expression of other factors that 
stimulates transcription of survivin transcription. Sp1/
Sp3 and NF-kB promoter binding surviving that interact 
with HIF-1 to regulate the expression of survivin.29
 Reactive oxygen species (ROS) also involved 
mitochondria-dependent signaling process is needed in 
hypoxia to promote HIF-1α stabilization. Also, mitochondrial 
ROS is required for HIF-1α-DNA binding or induction of 
erythropoietin (EPO)-mediated HIF-1α expression, VEGF 
and glycolytic enzyme. ROS increases angiogenesis by 
increasing HIF-1α and activation and expression of VEGF 
reseptor-2 (VEGFR2) as illustrated in Figure 2. Oxidative 
stress also induces VEGF-independently angiogenesis by 
an oxidative phospholipid or post-translational modification 
and resulting in metabolite acting as a ligand. Survivin 
expression is a downstream target of important HIF-1α 
because survivin function is needed to keep cell viability 
in the hypoxic condition. Thus, HIF-1α-dependent 
transcription of survivin can mediate the cell viability at 
low oxygen condition which due to tumor growth. Besides, 
increased survivin expression can contribute to VEGF 
synthesis in hypoxia by VEGF-A upregulation by HIF-1α 
and HIF-2α.4
Survivin mechanism in STAT3
STAT3 or 3’ transcription activator is an oncogenic 
transcriptional factor involved in cytokine signaling and a 
group of E2 factor (E2F) transcriptional factor functions in 
G1/synthesis(S) transition of cell cycle. STAT3 activated by 
cytokine or growth factors in various types of cancer and play 
a significant role in tumor cell proliferation, differentiation 
and defense. STAT3 can translocate into the nucleus and 
regulate transcription of specific target gene like survivin.30 
In primary lymphoma cells, STAT3 signaling inhibition 
may trigger apoptosis via a mechanism involving survivin 
transcription suppression. Many further studies found that 
STAT3 directly binds survivin promoter and regulate the 
expression. Survivin protein sequences have a lysine-rich 
region at the C-terminal, forming a primary platform for 
proteins interaction and modification at post-transitional 
level.31
Survivin surviving mechanism in Notch signaling pathway
Notch signaling is essential for cell development, 
differentiation, survival and proliferation of tissue 
morphogenesis. Impairment occurs in differentiation, 
survival regulation and or proliferation will cause 
transformation into malignant, so that pathophysiological 
Notch signal provides the contribution to cancer progression 
in some different ways. Notch signaling can regulate survivin 
expression, for example, Notch-1 signaling activated by 
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survivin expression under the influence of hypoxia inside 
non-small cell lung cancer (NSCLC). Notch-1 signaling 
activation associated to increased HIF-1α, which functions 
as a co-activator via its interaction with the activated form 
of Notch-1, Notch 1 intracellular domain (N1ICD) that 
facilitate relationship between recombination signal binding 
protein for immunoglobulin kappa J region (RBPJ) in the 
survivin promoter.32
Survivin mechanism in TGF-β signaling
Changes in cell behavior produce responsiveness not 
only from the genetic change like oncogenic activation or 
tumor suppressor gene inactivation, but also from altered 
production, or response to stimulation growth of differential 
factor. Among them, there is transforming growth factor 
beta (TGF-β) change and signal effector as the primary 
determinator of carcinoma cell behavior. Autocrine and 
paracrine effects of TGF-β occur in the tumor cell and 
provide both positive and negative influences in the 
environment of cancer progression. Thus, TGF-β signaling 
pathway plays roles as tumor pathway suppressor and 
progression promoter and tumor invasion. 
 TGF-β and its signaling effectors such as similar to 
mothers against decapentaplegic 2 (Smad2) and Smad3 
proteins are key factors in proliferation-controlling and 
tumor cell differentiation. Smad2 and Smad3 are activated 
via carboxy-terminal phosphorylation by type 1 TGF-β 
kinase receptor and form a heterotrimeric complex with 
Smad4. The formed complex will translocate into the 
nucleus and acts as an activator of TGF-β-induced target 
gene transcription. TGF-β is a tumor suppressor with its 
ability in cell growth inhibition via cell apoptosis.
 TGF-β identified as an important negative regulator 
of surviving. TGF-β signaling suppression by either TGF-β 
inhibitor receptor kinase or Smad2 and Smad3 silencing 
will induce survivin expression.33 On the contrary, survivin 
expression suppressed by TGF-β signaling pathway at the 
transcriptional level via Smad2 and 3-dependent mechanism 
and cell cycle-dependent element/cell cycle genes homology 
region (CDE/CHR) from survivin promoter leading to 
retinoblastoma hypophosphorylation via Smad3-dependent 
mechanism.34
HPV infection and survivin expression 
relationship
Is has been known that invasive cervical cancer is caused by 
HPV infection, especially HR-HPV type; mostly 16 and 18.35 
Recent studies have shown that HPV-16 have an important 
role in cervical tumorigenesis related to survivin.36 The most 
Figure 1. The survivin and VEGF connection through β-catenin 
pathway.4 (Adapted with permission from Springer Nature). 
shSurvivin: small hairpin Survivin, Akt-DN: Akt dominant-
negative form.
Figure 2. Upregulation of HIF-1α induce angiogenesis through 
VEGF in hypoxia.4 (Adapted with permission from Springer 
Nature). NADPH: nicotinamide adenine dinucleotide phosphate, 
TLR: toll-like receptors..
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important viral oncoprotein expressed by HPV-16 are E6 
and E7 and have any effect on the expression of the human 
survivin gene in cervical cancer cell lines. HPV-16 E6 
transactivates survivin promoter activity, and interestingly 
in the transient infection, it’s transactivated all the survivin 
reporter constructs. However, in a cell line which no express 
p53, there is no transactivation effect on the survivin reporter 
constructs, this may suggest that p53 has a role in mediating 
transactivation effect of E6 oncoprotein to the survivin 
promoter.37 It well established that HR-HPV E6 oncoprotein 
induces the proteosome-mediated degradation of p53,38 as a 
logical implication that HPV E6 transactivates the survivin 
promoter mediated by the presence of p53 degradation. On 
the other hand, E6 oncoprotein also induces endogenous 
survivin transcription indicated by the high level of survivin 
mRNA.37
Survivin as cervical cancer biomarker and 
target of therapy
Survivin as diagnostic marker
Cervical cancer is well diagnosed today by Papanicolau 
staining and allowed to grading CIN and determining SCC 
along HPV DNA testing. Several findings concluded that 
survivin has an ability to do the same thing with Papanicolau 
staining for diagnosing cervical cancer. Survivin has gradual 
increase expression level in every stage of CIN and showing 
a gradual increase compared to the normal cervix, CIN and 
cervical SCC as well.9,39   
 CIN is a condition of precancerous squamous cell that 
has a risk of malignant progression, which is higher in the 
high level of CIN and well correlated with the expression of 
survivin in every stage of CIN.40,41 It undoubted that survivin 
would be a potential marker to predict clinical condition 
and risk for cancerous cervix tissue, showed by correlation 
of survivin expression with HR-HPV. It suggested that 
survivin has an ability to differentiate causal of cervical 
lesion whether HR-HPV or low-risk HPV (LR-HPV) but 
still cannot substitute HPV testing in monitoring risk of 
disease recurrence after treatment.35   
 The level of Survivin expression determined by 
immunostaining technique and polymerase chain reaction 
(PCR) that supposed to be more objective interpretation than 
conventional staining because it would be relatively close to 
the quantitative result. A new approach method in detection 
of survivin expression is a molecular beacon or tagging 
with fluorescent that suggested giving the objective results 
because of interpreted based on fluorescent intensity.42 
As long as clinical research for survivin increased, more 
data collected can be more confidently propose survivin 
as a predictor for diagnosing cervical cancer and ability 
as a predictor, in combination with expression of p16 and 
phosphatase and tensin homolog (PTEN) would be more 
powerful.41 It is fascinating to make deeper exploration for 
survivin features in cervical cancer management. Another 
finding suggests that intracellular survivin well correlated 
to the progression of cervical cancer compared to nuclear 
survivin.43
Survivin as prognostic marker
Survivin expression recently was known have a close 
correlation with the occurrence, development and prognosis 
of cervical cancer.44 In most cervical cancer patients, 
survivin overexpression is correlated to poor survival 
rate and can predict aggression of cancerous tissue to the 
lymph node. The most correlated clinicopathological with 
the consistent result is clinical staging and lymph node 
metastasis, in contrast with Federation of Gynecology 
and Obstetrics (FIGO) stage, tumor size and age. Another 
data showed that high survivin is associated with reduced 
survival and supported by the clinical finding in the lung, 
gastric and esophageal cancer.45  
 Based on those results in the meta-analysis, survivin 
is suggested as a useful prognostic and tumor aggression 
marker for cervical cancer. Survivin also can predict the 
response of irradiation therapy as long as caspase-3 an 
advanced stage cervical cancer. Survivin is known as caspase 
inhibitor that inhibits apoptosis so that over-expression 
of survivin increases tumor cell resistance to irradiation 
and hypoxia.5 Survivin in well correlated with hypoxia 
condition, most of the tumor cell makes their surrounding 
be hypoxia, and well-known marker for hypoxia is HIF-1α. 
Survivin expression regulated by HIF-1α as a compensation 
mechanism of hypoxia; cell has to survive in hypoxic 
condition. The mechanism has enhanced the activity of HIF-
1α on survivin promoter.29 So that no wonder if survivin 
can predict resistance to therapy and hypoxia in advanced 
cervical cancer. Surivivin is also applicable to the early 
stage of cervical cancer so that would be better management 
of patients. Survivin known to make cancer cell resistance 
to radiation therapy, as same as to hypoxic condition, it is 
a compensation mechanism or adaptation to stress. The 
cancerous cell has evaluated in response to radiation level; 
high intensity suggested to increase survivin expression and 
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inhibit apoptosis so that radiation therapy efficacy would be 
not adequate.46  
 Based on the explanation above, there are other 
survivin features of effectiveness in the therapy of cervical 
cancer and to predict the intensity of radiation to keep tumor 
cells do not reach their adaptive response. Survivin also 
has an issue of cervical cancer resistance to chemotherapy. 
Survivin expression inversely proportional to sensitivity 
against cis-diamminedichloridoplatinum(II) (CDDP) and 
5-fluorouracil (5-FU) but more clinical data required to 
encourage the power of survivin to predict resistance to 
chemotherapy.47
Survivin as cervical cancer target therapy
Resistance to therapy becomes a big problem in cancer 
management. Survivin known plays a significant role 
in resistance as described above. Survivin inhibits cell 
apoptosis and as a consequence, the tumor grows rapidly 
and increasing expression of survivin is correlated to therapy 
resistance. Simply, survivin would be a target and biomarker 
for efficacy due to its features in clinicopathological 
and progression of cervical cancer.48 In recent years, 
considerable efforts have been made to validate survivin as 
a preferred target and prognostic marker in cancer therapy. 
Some studies have addressed the effects of interfering 
survivin expression, or in tumor cell function; for instance, 
introduction a dominant negative variant of survivin into 
cervical cancer cells caused the multipolar mitotic spindles, 
cytokinesis failure, the formation of multinucleated cells, 
reduced proliferation and induction of apoptosis.49
 In short, all of the approaches to survivin as a 
therapeutic target for cancer is interfering the biogenesis 
and function of survivin. Those strategies are started from 
inhibition of promoter or transcription factors, interfering 
transcripted mRNA that reduced translation grouped into 
nucleic acid base therapy, altering protein stability and post-
translational modification including protein folding and 
even more secondary modification and the most promising 
and save techniques are immunotherapy and genome 
editing.6,7,47
Inhibition of survivin transcription
Some transcription factors are known to recognize the 
specific response elements of survivin gene promoter and 
involved in the regulation of survivin mRNA regulation 
transcription. Thus, blocking the transcription of the 
survivin through inhibition of specific transcription factors 
suggested being a promising concept to interfere with 
survivin expression and function.49 Inhibitor transcription 
factor that selected from the compound library as an 
inhibitor of survivin promoter-reporter gene construct is 
sepantronium bromide (YM155).50,51 YM155 is the first 
small chemical molecule and known as a high selectivity 
inhibitory ability to survivin transcription with no activity 
against other anti-apoptotic molecules like cellular IAP 
(cIAP), XIAP or cIAP1.52 YM155 decreased survivin 
expression by repression of survivin promoter activity by 
binding to the transcription factor interleukin enhancer-
binding factor 3 (ILF3) and disrupting ILF/p54 complex. 
YM155 effectively reduced expression of survivin and also 
reduced lymph node metastasis in cervical cancer.13
 Another strategy in inhibiting survivin expression 
is interfering transcripted mRNA utilization including 
antisense oligonucleotide (AO), small interfering RNA 
(siRNA) and miRNA. AO are short single stranded RNA or 
DNA that complementary to as specific target mRNA which 
is survivin mRNA caused unable to translate into protein 
or even inhibiting at the protein level. The first attempt at 
AO therapy targeting survivin induced apoptosis in human 
cell melanoma cell lines and continued with another type 
of cancer such as lung, lymphoma, thyroid, head and neck 
cancer and cervical cancer as well.51,53
 The other promising approach in nucleotide-based 
survivin targeting is RNA interference (RNAi) such as 
siRNA which inhibits tumor growth by triggering apoptosis 
and commonly use for in vitro investigation to transfect 
to the survivin RNA. However, it has several limitations 
including disadvantages pharmacokinetic profile and 
ineffectively transfection into the cell and not affect a broad 
range of regulation compared to miRNA, so that miRNA 
more promising due to its ability to repress gene expression. 
An artificial miRNA has been developed to treat cervical 
cancer and show a good performance to arresting the cell 
cycle in G2/M, suppress survivin expression and increasing 
p53/p21 protein level.55 Among nucleotide therapeutic 
strategies, miRNA show a reliable result to repress survivin 
expression and its function to treat cervical cancer, but all of 
the approaches need to be established transfection method 
and it seems not practical.
Inhibition survivin at the post-translational level
The distinguishable function of survivin in cell activity most 
likely realized through the domain structure of the protein 
molecule and regulated by subsequent modifications such 
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as targeting enzyme that may interfere the process, altering 
folding and destabilizing survivin structure, or inhibiting 
phosphorylation of survivin.49 Based on the molecular 
pathway in nature of survivin, phosphorylation is the most 
common modification and play a critical role in survivin 
activity. For example, survivin phosphorylated at Thr117 by 
Aurora-B kinase and at Thr34 by polo-like kinase 1 (PLK-
1), both of that phosphorylation required for the correct 
spindle microtubule attachment. Thus, by inhibiting those 
enzymes, survivin activity may decrease and apoptosis will 
occur in the cancer cell.49,55
 The other strategy is inhibiting survivin at the post-
translational level through the inhibiting agent to CDK 
and heat shock protein 90 (Hsp90). Inhibiting CDK 
would repress survivin phosphorylation. Thus survivin 
will not be active and inhibiting Hsp90 would prevent 
survivin to make a complex with Hsp90. Shepherdin is a 
cell-permeable antagonist of the Hsp90 and inhibits its 
function by competing with adenosine triphosphate (ATP) 
binding.51 Destabilizing protein structure of survivin has 
known through Kirsten rat sarcoma viral oncogene homolog 
(K-Ras) mutation. Mutant K-Ras decrease survivin levels 
through ubiquitination and proteasomal degradation.56 
There is no sufficient data in treating cervical cancer using 
a post-translational modification of survivin but based on 
explained pathway above, we can see that mechanism of 
every cancer is same all the way, so that this approach also 
have a contribution in treating cervical cancer.
Immunotherapy and vaccine
The immune system of human broadly divided into two 
groups, which is innate and adaptive immunity and further, 
adaptive immunity consists of cell-mediated immunity and 
humoral immunity. Adaptive immunity has been explored 
to become a potential approach in immune therapy for 
malignancy, especially cervical cancer. The fundamental 
approach based on specific recognition of tumor-associated 
antigen by cytotoxic T lymphocytes (CTL) which activated 
by presented dendritic cells.57,58 About 30% of cervical 
cancer patients will experience failure therapy including 
surgery, radiotherapy and chemotherapy, as described 
above, survivin have an important role in that condition.59 
For that, targeting survivin immunological is very promising 
for treating cervical cancer and another cancer because of 
survivin suggested being a universal antigen for tumor based 
on the first evidence that survivin can induce specific CTL in 
vitro when the protein processed and presented by dendritic 
cells.60 Cancer cells containing a lot of survivin including 
cervical cancer cells, after survivin epitopes recognized by 
CTL and then neutralized, the number of survivin decrease 
and apoptosis of cancer cell not inhibited. While CTL 
response is powerful as anti-tumor targeting agents, CTL 
response has not led to consistent clinical responses, so that 
some studies have evaluated the value of CD4+ T-cells, once 
CD4+ cells have activated. The release of many cytokines 
and enhanced CTL immune response, therefore, a vaccine 
strategy that combining CTL and CD4+ cells improved 
survivin targeted vaccination approach.10 Immunotherapy 
for cervical cancer suggested to non-invasive way with 
good efficacy compared to chemotherapy or radiotherapy 
that known non-selective and made patients more suffer due 
to their side effects.
Gene therapy
The last strategy and still become a field of interest and the 
most promising, which is gene therapy. There are two main 
approaches have been developed for targeting survivin with 
gene editing. One based on the activation of apoptosis in 
tumor cell infected with survivin-containing vector and 
expression of cytotoxic gene driven by survivin promoter in 
the tumor cell.61 An example of essential gene therapy has 
transfected a plasmid encoding a nonphosphorylated Thr34 
mutated to alanine using replication-deficient adenovirus; 
this approach is selective and efficient to repress survivin 
in HeLa cell line and application at dysregulated apoptotic 
balance in cervical cancer patients.62 Recent development 
in gene therapy is genome editing. This approach is more 
promising and safer than the previous methods. There are 
three genome-editing techniques have been developed 
today; zinc-finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs) and clustered regularly 
interspaced short palindromic repeats-associated protein-9 
nuclease (CRISPR/Cas-9).51 To date, CRISPR/Cas9 system 
suggested to be a versatile system for genome editing, in the 
case of cancer, survivin has a high expression that inhibits 
apoptosis, suppressing the expression of survivin would be 
more easy, high specificity and less side effect. 
 Recent findings show that CRISPR/Cas9 application 
to fight cervical cancer started from the beginning; HPV 
infection to the therapy after cancer promoted. In one 
study, HeLa and SiHa cervical cancer contained HPV18 
and HPV16 genome. Inactivating deletion and insertion 
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mutations were induced in E6 and E7 resulting activation 
of p53 and resulting cell cycle arrest.63 Due to arresting cell 
cycle ability, survivin has also involved in that process so 
that survivin expression would repress as well after Cas9 
introduction. There is no sufficient data in application 
genome editing to cervical cancer patients to date, but based 
on its performance and all of the advantages, cervical cancer 
treatment has a light of hope at the end of a tunnel. 
Conclusion
Cervical cancer is one of cancer promoted by virus 
infection especially HR-HPV type 16 and 18 expressed E6 
oncoprotein. The unique link between HPV infection with 
survivin expression and regulation is fascinating. Survivin 
plays a significant role in every step of cervical and other 
cancer progressions through standard mechanisms. Survivin 
has many features in cervical cancer management, started 
from diagnosis, prognosis and therapy.
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